Loading clinical trials...
Loading clinical trials...
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Start Date
April 30, 2025
Primary Completion Date
April 1, 2027
Completion Date
April 1, 2027
Last Updated
April 8, 2025
PET
DIAGNOSTIC_TEST
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
NCT06305754
NCT07486219
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06987890